117095-81-5

Basic information

• Product Name: 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester
• Synonyms: 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester
• CAS NO: 117095-81-5
• Molecular Weight: 271.273
• Mol File: 117095-81-5.mol

Chemical Properties

• CAS DataBase Reference: 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester(117095-81-5)
• EPA Substance Registry System: 4-phenyl-2,6-pyridinedicarboxylic acid dimethyl ester(117095-81-5)

Safety Data

• Hazardous Substances Data: 117095-81-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 83463-12-1 4-phenyl-2,6-pyridinedicarboxylic acid 
• 247210-81-7 4-trifluoromethanesulfonyloxy-pyridine-2,6-dicarboxylic acid dimethyl ester 
• 98-80-6 phenylboronic acid 
• 5371-70-0 dimethyl 4-chloro-2,6-pyridinedicarboxylate 
• 71022-75-8 4-chloropyridine-2,6-dicarbonyl dichloride 
• 138-60-3 chelidamic acid 
• 20443-03-2 4-oxo-1,4-dihydro-pyridine-2,6-dicarboxylic acid dimethyl ester 
• 3044-71-1 2,6-dimethyl-4-phenylpyridine 
• 1225287-43-3 phenylmagnesium bromide 
• 499-51-4 Chelidamic acid 
• 162102-79-6 dimethyl 4-bromo-2,6-pyridinedicarboxylate 
• 19872-91-4 dimethyl 4-hydroxypyridine-2,6-dicarboxylate 

Downstream Products

• 117095-83-7 2,6-bis(hydroxymethyl)-4-phenylpyridine 
• 83463-12-1 4-phenyl-2,6-pyridinedicarboxylic acid 
• 247210-88-4 2,6-bis-chloromethyl-4-phenyl-pyridine 
• 247210-98-6 15-phenyl-3,11-bis-(toluene-4-sulfonyl)-3,7,11,17-tetraaza-bicyclo[11.3.1]heptadeca-1⁽¹⁶⁾,13⁽¹⁷⁾,14-triene 
• 247210-93-1 [15-phenyl-3,11-bis-(toluene-4-sulfonyl)-3,7,11,17-tetraaza-bicyclo[11.3.1]heptadeca-1⁽¹⁶⁾,13⁽¹⁷⁾,14-trien-7-yl]-phosphonic acid diethyl ester 
• 117095-84-8 4-phenyl-bis(2,6-bromomethyl)pyridine 
• 117095-88-2 4-phenyl-2,6-pyrido-27-crown-9 
• 1313379-55-3 C₁₇H₁₇Cl₂N₃O₂ 
• 1282036-84-3 (S,4S,4'S)-2,2'-(4-phenylpyridine-2,6-diyl)bis(4-sec-butyl-4,5-dihydrooxazole) 
• 1282036-89-8 2,2'-(4-phenylpyridine-2,6-diyl)bis(4,5-dihydrooxazole) 
• 1313379-53-1 C₂₅H₃₃Cl₂N₃O₂ 
• 717124-11-3 4-phenylpyridine-2,6-dicarboxaldehyde 

Relevant articles and documents

FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF

The present invention relates to fused heterocyclic derivatives, processes for their preparation and their use in medicine. Specifically, the present invention relates to a novel derivative represented by the formula (I′), or its pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the derivative or its pharmaceutically acceptable salt thereof, and the method for preparing the derivative and its pharmaceutically acceptable salt thereof. The present invention also relates to the use of the derivative and its pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the derivative and its pharmaceutically acceptable salt thereof in the preparation of medicines, in particularly as IDO inhibitor medicines, for treating and/or preventing cancers. Wherein each substituent of the formula (I′) is the same as defined in the specification.

Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1

The efficacy of β-lactam antibiotics is threatened by the emergence and global spread of metallo-β-lactamase (MBL) mediated resistance, specifically New Delhi metallo-β-lactamase-1 (NDM-1). By utilization of fragment-based drug discovery (FBDD), a new class of inhibitors for NDM-1 and two related β-lactamases, IMP-1 and VIM-2, was identified. On the basis of 2,6-dipicolinic acid (DPA), several libraries were synthesized for structure-activity relationship (SAR) analysis. Inhibitor 36 (IC50 = 80 nM) was identified to be highly selective for MBLs when compared to other Zn(II) metalloenzymes. While DPA displayed a propensity to chelate metal ions from NDM-1, 36 formed a stable NDM-1:Zn(II):inhibitor ternary complex, as demonstrated by 1H NMR, electron paramagnetic resonance (EPR) spectroscopy, equilibrium dialysis, intrinsic tryptophan fluorescence emission, and UV-vis spectroscopy. When coadministered with 36 (at concentrations nontoxic to mammalian cells), the minimum inhibitory concentrations (MICs) of imipenem against clinical isolates of Eschericia coli and Klebsiella pneumoniae harboring NDM-1 were reduced to susceptible levels.

Nickel-Catalyzed reductive cross-Coupling of unactivated alkyl halides

A Ni-catalyzed reductive approach to the cross-coupling of two unactivated alkyl halides has been successfully developed. The reaction works efficiently for primary and secondary halides, with at least one being bromide. The mild reaction conditions allow for excellent functional group tolerance and provide the C(sp3)-C(sp3) coupling products in moderate to excellent yields.

Ruthenium-catalyzed asymmetric epoxidation of olefins using H 2O2, part I: Synthesis of new chiral N,N,N,-tridentate pybox and pyboxazine ligands and their ruthenium complexes

The synthesis of chiral tridentate N,N,N-pyridine-2.6-bisoxazolines 3 (pyhox ligands) and N,N,N-pyridine-2.6-bisoxazines 4 (pyboxazine ligands) is described in detail. These novel ligands constitute a useful tool-box for the application in asymmetric catalysis. Compounds 3 and 4 are conveniently prepared by cyclization of enantiomerically pure α- or β-amino al cohols with dimethyl pyridine-2,6-dicarboximidate. The corresponding ruthenium complexes are efficient asymmetric epoxidation catalysts and have been prepared in good yield and fully char acterized by spectroscopic means. Four of these ruthenium complexes have been characterized by X-ray crystallography. For the first time the molecular structure of a pyboxazine complex (2,6-bis-[(4S)-4-phenyl-5,6- dihydro-4H-[1,3]oxazinyl]pyridine)(pyridine-2,6-dicarboxylate)ruthenium (S)-2aa, is presented.

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV- 2 replication by antagonism of the chemokine receptor CXCR4

Bis-tetraazamacrocycles such as the bicyclam AMD3100 are a class of potent and selective anti-HIV-1 and HIV-2 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the co-receptor for entry of X4 viruses. With the aim of optimi